2025 annual financial data
Lyell Immunopharma 2025 Net margin
Direct answer
Net margin was -762,355.56%.
Operating income was -203.77M USD and net income was -274.45M USD.
Operating cash flow was -150.02M USD.
Get free Lyell Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 36,000 USD
- Operating income
- -203.77M USD
- Net income
- -274.45M USD
- Operating cash flow
- -150.02M USD